{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T16:39:26Z","timestamp":1770827966543,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,8]],"date-time":"2020-08-08T00:00:00Z","timestamp":1596844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,8]],"date-time":"2020-08-08T00:00:00Z","timestamp":1596844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Autologous hematopoietic stem cell transplantation (aHSCT) is a treatment option for a selected group of systemic sclerosis (SSc) patients with good available evidence but can be associated with considerable morbidity and mortality. The aim of this study was to describe infectious complications and distinct immune reconstitution patterns after aHSCT and to detect risk factors in lymphocyte subsets, which are associated with an elevated rate of infections after aHSCT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Seventeen patients with SSc were included in this single-center retrospective cohort study. Clinical and laboratory data was collected before and for 12\u2009months after aHSCT, including immunophenotyping of peripheral whole blood by fluorescence-activated cell sorting.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Cytomegalovirus (CMV) reactivations were common in CMV-IgG-positive patients (50%) and needed treatment. Mycotic infections occurred in 17.6%. One patient died (resulting in a mortality of 5.9%) due to pneumonia with consecutive sepsis. All patients showed decreased T helper cells (CD3<jats:sup>+<\/jats:sup>\/CD4<jats:sup>+<\/jats:sup>) and within the B cell compartment decreased post-switched memory B cells (CD19<jats:sup>+<\/jats:sup>\/CD27<jats:sup>+<\/jats:sup>\/IgD<jats:sup>\u2212<\/jats:sup>) and elevated na\u00efve B cells (CD19<jats:sup>+<\/jats:sup>\/CD27<jats:sup>\u2212<\/jats:sup>\/IgD<jats:sup>+<\/jats:sup>) until 12\u2009months after aHSCT. Patients who developed infections had significantly lower B cells before aHSCT than patients who did not develop infections.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>After aHSCT, monitoring for infectious complications, especially for CMV reactivations, is crucial as the reconstitution of the immune system takes longer than 12\u2009months. Low peripheral B cells might be a risk factor for an elevated infection rate.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-020-02255-3","type":"journal-article","created":{"date-parts":[[2020,8,8]],"date-time":"2020-08-08T06:02:34Z","timestamp":1596866554000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Low B cell counts as risk factor for infectious complications in systemic sclerosis after autologous hematopoietic stem cell transplantation"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0074-4459","authenticated-orcid":false,"given":"Michael","family":"Gernert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Peter","family":"Tony","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva Christina","family":"Schwaneck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Fr\u00f6hlich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Schmalzing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,8]]},"reference":[{"key":"2255_CR1","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1093\/rheumatology\/ker269","volume":"51","author":"M Elhai","year":"2012","unstructured":"Elhai M, Meune C, Avouac J, Kahan A, Allanore Y. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford). 2012;51:1017\u201326.","journal-title":"Rheumatology (Oxford)"},{"key":"2255_CR2","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","volume":"390","author":"CP Denton","year":"2017","unstructured":"Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390:1685\u201399.","journal-title":"Lancet"},{"issue":"6","key":"2255_CR3","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1002\/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I","volume":"44","author":"JE Pope","year":"2001","unstructured":"Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum. 2001;44(6):1351\u20138.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"2255_CR4","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327\u201339.","journal-title":"Ann Rheum Dis"},{"key":"2255_CR5","doi-asserted-by":"crossref","unstructured":"Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC et al. Sclerodema Lung Study II Investigators. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 2016;4:708\u2013719.","DOI":"10.1016\/S2213-2600(16)30152-7"},{"key":"2255_CR6","doi-asserted-by":"crossref","unstructured":"Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE et al. Scleroderma Lung Study Research Group.Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655\u20132666.","DOI":"10.1056\/NEJMoa055120"},{"issue":"12","key":"2255_CR7","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1093\/rheumatology\/key213","volume":"57","author":"G Sircar","year":"2018","unstructured":"Sircar G, Goswami RP, Sircar D, Ghosh A, Ghosh P. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. Rheumatology (Oxford). 2018;57(12):2106\u201313.","journal-title":"Rheumatology (Oxford)"},{"key":"2255_CR8","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.semarthrit.2016.10.003","volume":"46","author":"D Daoussis","year":"2017","unstructured":"Daoussis D, Melissaropoulos K, Sakellaropoulos G, Antonopoulos I, Markatseli TE, Simopoulou T, et al. A multicenter, open-label, comparative study of B-cell depletion therapy with rituximab for systemic sclerosis-associated interstitial lung disease. Arthritis Rheum. 2017;46:625\u201331.","journal-title":"Arthritis Rheum"},{"key":"2255_CR9","unstructured":"Khanna D, Lin CJF, Kuwana M, Allanore Y, Batalov A, Butrimiene I, et al. Efficacy and safety of tocilizumab for the treatment of systemic sclerosis: results from a phase 3 randomized controlled trial [abstract]. Arthritis Rheumatol. 2018;70(suppl 10) https:\/\/acrabstracts.org\/abstract\/efficacy-and-safety-of-tocilizumab-for-the-treatment-of-systemic-sclerosis-results-from-a-phase-3-randomized-controlled-trial\/. Accessed June 6, 2020."},{"key":"2255_CR10","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","volume":"378","author":"RK Burt","year":"2011","unstructured":"Burt RK, Shah SJ, Dill K, Grant T, Gheorghiade M, Schroeder J, et al. Autologous non-myeloablativehaemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet. 2011;378:498\u2013506.","journal-title":"Lancet"},{"key":"2255_CR11","doi-asserted-by":"crossref","unstructured":"Van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, et al. EBMT\/EULAR Scleroderma Study Group. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 2014;311:2490\u20132498.","DOI":"10.1001\/jama.2014.6368"},{"key":"2255_CR12","doi-asserted-by":"crossref","unstructured":"Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B et al. SCOT Study Investigators.Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med 2018;378:35\u201347.","DOI":"10.1056\/NEJMoa1703327"},{"issue":"1","key":"2255_CR13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13075-019-1823-0","volume":"21","author":"M Ayano","year":"2019","unstructured":"Ayano M, Tsukamoto H, Mitoma H, Kimoto Y, Akahoshi M, Arinobu Y, et al. CD34-selected versus unmanipulated autologous haematopoietic stem cell transplantation in the treatment of severe systemic sclerosis: a post hoc analysis of a phase I\/II clinical trial conducted in Japan. Arthritis Res Ther. 2019;21(1):30.","journal-title":"Arthritis Res Ther."},{"key":"2255_CR14","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F Van den Hoogen","year":"2013","unstructured":"Van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65:2737\u201347.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"2255_CR15","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/j.1399-3062.2009.00401.x","volume":"11","author":"K Kohno","year":"2009","unstructured":"Kohno K, Nagafuji K, Tsukamoto H, Horiuchi T, Takase K, Aoki K, et al. Infectious complications in patients receiving autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Transpl Infect Dis. 2009;11(4):318\u201323.","journal-title":"Transpl Infect Dis"},{"issue":"2","key":"2255_CR16","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/j.1600-0609.2005.00569.x","volume":"76","author":"P Fr\u00e8re","year":"2006","unstructured":"Fr\u00e8re P, Pereira M, Fillet G, Beguin Y. Infections after CD34-selected or unmanipulated autologous hematopoietic stem cell transplantation. Eur J Haematol. 2006;76(2):102\u20138.","journal-title":"Eur J Haematol"},{"issue":"4","key":"2255_CR17","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/bmt.2015.316","volume":"51","author":"KM Williams","year":"2016","unstructured":"Williams KM, Ahn KW, Chen M, Aljurf MD, Agwu AL, Chen AR, et al. The incidence, mortality and timing of Pneumocystis jiroveci pneumonia after hematopoietic cell transplantation: a CIBMTR analysis. Bone Marrow Transplant. 2016;51(4):573\u201380.","journal-title":"Bone Marrow Transplant"},{"key":"2255_CR18","doi-asserted-by":"publisher","unstructured":"Messiaen PE, Cuyx S, Dejagere T, van der Hilst JC. The role of CD4 cell count as discriminatory measure to guide chemoprophylaxis against Pneumocystis jirovecii pneumonia in human immunodeficiency virus-negative immunocompromised patients: a systematic review. Transpl Infect Dis. 2017;19(2). https:\/\/doi.org\/10.1111\/tid.12651. Epub 2017 Feb 15.","DOI":"10.1111\/tid.12651"},{"key":"2255_CR19","doi-asserted-by":"publisher","unstructured":"Henes J, Oliveira MC, Labopin M, Badoglio M, Scherer HU, Del Papa N, et al. Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party. Haematologica. 2020. https:\/\/doi.org\/10.3324\/haematol.2019.230128. Online ahead of print.","DOI":"10.3324\/haematol.2019.230128"},{"issue":"1","key":"2255_CR20","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/eji.201948129","volume":"50","author":"M Van der Kroef","year":"2020","unstructured":"Van der Kroef M, Van den Hoogen L, Mertens J, Blokland S, Haskett S, Devaprasad A, et al. Cytometry by time of flight identifies distinct signatures in patients with systemic sclerosis, systemic lupus erythematosus and Sj\u00f6grens syndrome. Eur J Immunol. 2020;50(1):119\u201329.","journal-title":"Eur J Immunol"},{"issue":"7","key":"2255_CR21","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s10067-017-3597-6","volume":"36","author":"A Lescoat","year":"2017","unstructured":"Lescoat A, Lecureur V, Roussel M, Sunnaram B, Ballerie A, Coiffier G. CD16-positive circulating monocytes and fibrotic manifestations of systemic sclerosis. Clin Rheumatol. 2017;36(7):1649\u201354.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"2255_CR22","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13075-019-1889-8","volume":"21","author":"M Gernert","year":"2019","unstructured":"Gernert M, Tony HP, Schwaneck EC, Gadeholt O, Schmalzing M. Autologous hematopoietic stem cell transplantation in systemic sclerosis induces long-lasting changes in B cell homeostasis toward an anti-inflammatory B cell cytokine pattern. Arthritis Res Ther. 2019;21(1):106.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"2255_CR23","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1002\/art.21036","volume":"52","author":"D Farge","year":"2005","unstructured":"Farge D, Henegar C, Carmagnat M, Daneshpouy M, Marjanovic Z, Rabian C, et al. Analysis of immune reconstitution after autologous bone marrow transplantation in systemic sclerosis. Arthritis Rheum. 2005;52(5):1555\u201363.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2255_CR24","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1182\/blood-2008-07-168286","volume":"113","author":"T Alexander","year":"2009","unstructured":"Alexander T, Thiel A, Rosen O, Massenkeil G, Sattler A, Kohler S, et al. Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood. 2009;113(1):214\u201323.","journal-title":"Blood."},{"issue":"3","key":"2255_CR25","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/cei.12985","volume":"189","author":"FG Karnell","year":"2017","unstructured":"Karnell FG, Lin D, Motley S, Duhen T, Lim N, Campbell DJ, et al. Reconstitution of immune cell populations in multiple sclerosis patients after autologous stem cell transplantation. Clin Exp Immunol. 2017;189(3):268\u201378.","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"2255_CR26","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1002\/1529-0131(200104)44:4<754::AID-ANR131>3.0.CO;2-N","volume":"44","author":"RJ Verburg","year":"2001","unstructured":"Verburg RJ, Kruize AA, van den Hoogen FH, Fibbe WE, Petersen EJ, Preijers F, et al. High-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with rheumatoid arthritis: results of an open study to assess feasibility, safety, and efficacy. Arthritis Rheum. 2001;44(4):754\u201360.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"2255_CR27","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1182\/blood.V92.5.1471","volume":"92","author":"T Guillaume","year":"1998","unstructured":"Guillaume T, Rubinstein DB, Symann M. Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood. 1998;92(5):1471\u201390.","journal-title":"Blood."},{"issue":"8","key":"2255_CR28","first-page":"832","volume":"85","author":"H Steingrimsdottir","year":"2000","unstructured":"Steingrimsdottir H, Gruber A, Bj\u00f6rkholm M, Svensson A, Hansson M. Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications. Haematologica. 2000;85(8):832\u20138.","journal-title":"Haematologica."},{"key":"2255_CR29","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jcrc.2018.01.013","volume":"45","author":"C Krautz","year":"2018","unstructured":"Krautz C, Maier SL, Brunner M, Langheinrich M, Giamarellos-Bourboulis EJ, Gogos C, et al. Reduced circulating B cells and plasma IgM levels are associated with decreased survival in sepsis - a meta-analysis. J Crit Care. 2018;45:71\u20135.","journal-title":"J Crit Care"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02255-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-020-02255-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02255-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T23:12:36Z","timestamp":1628377956000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-020-02255-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,8]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2255"],"URL":"https:\/\/doi.org\/10.1186\/s13075-020-02255-3","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,8]]},"assertion":[{"value":"15 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was a retrospective cohort study, which is why approval by the local ethics committee of the University of W\u00fcrzburg was not mandatory. Solely routine parameters (for a tertiary referral center) were implemented in this analysis, which is why obtaining informed consent was not necessary according to German law. All data was generated in compliance with the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MG received travel grants from AbbVie, Chugai, Eli Lilly, Hexal, Janssen, Pfizer, and Roche.H-PT received speaker\u2019s fees, travel grants, research funding, or compensation for consultancies or board memberships from AbbVie, Chugai\/Roche, Eli Lilly, Gilead, Janssen, Novartis, Sandoz\/Hexal, Sanofi Aventis, and Takeda (Shire).ECS received speaker\u2019s fees, travel grants, research funding, or compensation for consultancies or board memberships from AbbVie, Chugai\/Roche, Janssen-Cilag, Eli Lilly, Novartis, and Takeda (Shire).MF received travel grants from AbbVie, Novartis, Janssen, and Eli Lilly and compensation for board memberships from AbbVie.MS received speaker\u2019s fees, travel grants, research funding, or compensation for consultancies or board memberships from AbbVie, Actelion, BMS, Boehringer\/Ingelheim, Celgene, Chugai\/Roche, Eli Lilly, Genzyme, Gilead, Hexal\/Sandoz, Janssen-Cilag, MSD, Novartis, Pfizer, Sanofi Pasteur, Takeda (Shire), and UCB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"183"}}